Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

a monoclonal antibody that helps further target the CAR-NK cells to lymphoma cells. A total of 10 study participants experienced low-grade cytokine release syndrome, a side effect of immunotherapy ...

Pathologically, NK-cell lymphomas are divided into extranodal NK-/T-cell lymphoma, nasal type and aggressive NK-cell leukemia by the WHO classification. Clinically, NK-cell lymphomas can be ...

A phase 1 clinical trial found one such immunotherapy to be safe for patients with several types of B-cell lymphoma ... cell called a natural killer (NK) cell. For the new therapy, these cells ...

a monoclonal antibody that helps further target the CAR-NK cells to lymphoma cells. A total of 10 study participants experienced low-grade cytokine release syndrome, a side effect of immunotherapy ...

NKure Therapeutics, a Bengaluru-based cell and gene therapy start-up, is trying to address this problem by working on ...

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper ...

This is compared to 83% ... Trial of Cell-Based Therapy for High-Risk Lymphoma Leads to FDA Breakthrough Designation July 10, 2024 — CAR-T cell therapy helps some with intractable lymphoma ...